Late Treatment Effects and Cancer Survivor Care in the Young: From Childhood to Early Adulthood

419 Pages·2021·10.73 MB·English

by  Jörn D. Beck, Carsten Bokemeyer, Thorsten Langer

Late Treatment Effects
and Cancer Survivor
Care in the Young
From Childhood to Early
Adulthood
Jörn D. Beck
Carsten Bokemeyer
Thorsten Langer
Editors
123
Late Treatment Effects and Cancer
Survivor Care in the Young
Jörn D. Beck • Carsten Bokemeyer
Thorsten Langer
Editors
Late Treatment Effects
and Cancer Survivor
Care in the Young
From Childhood to Early Adulthood
Editors
Jörn D. Beck Carsten Bokemeyer
Pediatric Hematology and Oncology Department of Onkology
University Hospital for Children University Hospital Hamburg-Eppendorf
and Adolescents Hamburg
Erlangen Germany
Germany
Thorsten Langer
Pediatric Oncology and Hematology –
Long-Term Follow-Up after Childhood
Cancer
University Hospital for Children
and Adolescents
Lübeck
Germany
ISBN 978-3-030-49138-3 ISBN 978-3-030-49140-6 (eBook)
https://doi.org/10.1007/978-3-030-49140-6
© Springer Nature Switzerland AG 2021
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or
part of the material is concerned, specifically the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way,
and transmission or information storage and retrieval, electronic adaptation, computer software,
or by similar or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specific statement, that such names are
exempt from the relevant protective laws and regulations and therefore free for general use.
The publisher, the authors, and the editors are safe to assume that the advice and information in
this book are believed to be true and accurate at the date of publication. Neither the publisher nor
the authors or the editors give a warranty, expressed or implied, with respect to the material
contained herein or for any errors or omissions that may have been made. The publisher remains
neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Contents
Part I Causes and Course of Severe Late Effects
1 Cardiotoxicity After Childhood Cancer Treatment . . . . . . . . . . . 3
Kelley K. Hutchins, Rudolf Steiner, Emma R. Lipshultz,
Stephen E. Sallan, and Steven E. Lipshultz
2 Kidney Disease in Childhood Cancer Survivors . . . . . . . . . . . . . 17
Roderick Skinner and Lars Hjorth
3 Ototoxicity After Childhood Cancer . . . . . . . . . . . . . . . . . . . . . . . 27
Amélie Tillmanns, Claudia Lanvers-Kaminsky, Ross Parfitt,
Annelot Meijer, Miklós Tóth, Adrian Münscher, Jörn D. Beck,
Marry van den Heuvel-Eibrink, and Antoinette am
Zehnhoff-Dinnesen
4 Complications in Tumour Orthopaedics . . . . . . . . . . . . . . . . . . . . 49
Jendrik Hardes and Arne Streitbürger
5 Causes and Course of Severe Late Effects in Young Cancer
Patients: Gastrointestinal Tract . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Alexander Stein
6 Pulmonary Toxicity: Causes and Course of Severe
Late Effects in the Lungs of Young Cancer Patients . . . . . . . . . . 61
Jennifer E. Agrusa and Andrew C. Dietz
7 Growth Hormone Deficiency in Young Cancer
Survivors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Stéphanie Espiard, Marianne Jarfelt,
and Gudmundur Johannsson
8 Endocrine Late Effects in Young Cancer Patients:
Thyroid Gland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Georg Brabant and Helmuth G. Dörr
9 Disorders of Gonadal and Reproductive Function
in Survivors of Childhood and Adolescent Cancer . . . . . . . . . . . 87
Christian Denzer
v
vi Contents
10 Fertility Protection in Childhood, Adolescents and Young
Adulthood Cancer Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Sebastian Findeklee and Michael von Wolff
11 Endocrine Late Effects in Young Cancer Patients:
Adrenal Gland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Helmuth G. Dörr and Georg Brabant
12 Pregnancy and Birth After Cancer in the Youth . . . . . . . . . . . . . 107
Magdalena Balcerek, Anja Borgmann-Staudt,
Sebastian Findeklee, and Michael von Wolff
13 Obesity and Metabolic Syndrome After Childhood
and Adolescent Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Christian Denzer, Judith Gebauer, and Georg Brabant
14 Subsequent Primary Cancer After Childhood,
Teenage and Young Adult Cancer . . . . . . . . . . . . . . . . . . . . . . . . . 125
Michael M. Hawkins, Clare Frobisher, Raoul C. Reulen,
and David L. Winter
15 Neuropsychological Short Assessment
of Disease- and Treatment-Related Intelligence
Deficits in Children with Brain Tumors . . . . . . . . . . . . . . . . . . . . 137
Holger Ottensmeier, Bernhard Zimolong,
and Paul G. Schlegel
16 Long-Term Positive and Negative Psychosocial
Outcome in Young Cancer Survivors
and Their Healthy Peers: Posttraumatic Stress
Disorder/Somatoform Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Mandy Niemitz, Dunja Tutus, and Jörg M. Fegert
17 Cancer-Related Fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
Judith Gebauer, Jens U. Rüffer, and Georg Brabant
Part II D iagnostics in the Detection of Late Effects in Different
Cancer Entities in Children, Adolescents and Young Adults
18 Late Effects After Treatment of Acute Lymphoblastic
Leukemia in Childhood and Adolescence . . . . . . . . . . . . . . . . . . . 169
Franziska Cuntz and Gabriele Escherich
19 Late Effects after Treatment of Acute Myeloid
Leukemia in Childhood and Adolescence . . . . . . . . . . . . . . . . . . . 183
Ursula Creutzig and Wolfgang Hiddemann
20 Side Effects and Sequelae of Treatment for Chronic
Myeloid Leukemia in Childhood and Adolescence . . . . . . . . . . . 189
Meinolf Suttorp and Markus Metzler
Contents vii
21 Late Effects After Treatment of Non-Hodgkin Lymphoma
in Childhood and Adolescents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207
Thorsten Langer and Christian Mueller
22 Late Effects After Treatment of Hodgkin Lymphoma
in Childhood and Adolescence . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
Ulrike Hennewig, Dieter Körholz, and Christine
Mauz-Körholz
23 Late Effects in Langerhans Cell Histiocytosis
of Young Cancer Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
Milen Minkov and Stephan Ladisch
24 Diagnostics and Diagnosis of Late Effects in Childhood
Brain Tumour Survivors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
Gesche Tallen, Martin Mynarek, Tanja Tischler,
Michael Weller, and Stefan Rutkowski
25 Late Effects in Children and Adolescents
with Neuroblastoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253
Frank Berthold
26 Late Effects in Children and Adolescents
with Nephroblastoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261
Norbert Graf
27 Late Effects After Treatment of
Hepatoblastoma and Hepatocellular Carcinoma
in Childhood and Adolescents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 273
Irene Schmid, Beate Häberle, and Dietrich von Schweinitz
28 Long-Term Sequelae After Retinoblastoma
in Childhood and Adolescents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279
Petra Ketteler and Eva Biewald
29 Late Effects in Children and Adolescents
with Ewing Sarcoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287
Uta Dirksen, Beate Timmermann, and Jendrik Hardes
30 Late Effects in Children and Adolescents
with Osteosarcoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299
Stefan S. Bielack, Stefanie Hecker-Nolting, and Jörn D. Beck
31 Late Effects in Children and Adolescents
with Soft Tissue Sarcoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311
Monika Sparber-Sauer and Thomas Klingebiel
32 Potential Late Effects of Rhabdoid Tumor
Therapy in Childhood and Adolescents . . . . . . . . . . . . . . . . . . . . 331
Karolina Nemes and Michael C. Frühwald
viii Contents
33 Late Effects After Treatment of Malignant Endocrine
Tumors in Childhood and Adolescents . . . . . . . . . . . . . . . . . . . . . 343
Antje Redlich, Peter Bucsky, and Peter Vorwerk
34 Skin Cancer in Childhood and Adolescents:
Treatment and Implications for the Long- Term Follow-Up . . . . 349
Lucie Heinzerling and Thomas Kurt Eigentler
35 Late Effects in Young Breast Cancer Survivors . . . . . . . . . . . . . . 357
Michael P. Lux, Diana Lüftner, and Dominik T. Schneider
36 Long-Term Effects of Colorectal Carcinoma
in Childhood and Adolescents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365
Andreas Block and Ines B. Brecht
Part III F inal Remarks and Outlook
37 Genetic Predisposition to Late Effects:
Pharmacogenomics of Cisplatin-Induced Ototoxicity . . . . . . . . . 377
Claudia Lanvers-Kaminsky, Marry van den Heuvel-Eibrink,
Annelot Meijer, Oliver Zolk, and Antoinette am
Zehnhoff-Dinnesen
38 Physical Activity, Exercise and Sports in Young
Cancer Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385
Miriam Götte, Sabine Kesting, and Joachim Boos
39 Developments and Risk-Adapted Strategies
in Modern Pediatric Radiotherapy . . . . . . . . . . . . . . . . . . . . . . . . 393
Beate Timmermann
40 Late Effects After Radiotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . 401
Diana Steinmann
41 Long-Term Follow-Up of Childhood Cancer
Patients from the Point of View of a Person Affected . . . . . . . . . 417
Christian Mueller
42 Networks of Survivorship Care for Young Cancer Patients . . . . 421
Jörn D. Beck, Lars Hjorth, and Thorsten Langer
43 Survivors in Their Social Environment After
Cure of Cancer at Young Age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427
Katja Baust, Romy Streppel, and Gabriele Calaminus
44 Long-Term Follow-Up Guidelines and Organization
of Long-Term Follow-Up Care for Childhood
and Young Adult Cancer Survivors . . . . . . . . . . . . . . . . . . . . . . . . 435
Thorsten Langer, Jörn D. Beck, Alex Stein,
Carsten Bokemeyer, and Judith Gebauer
Part I
Causes and Course of Severe Late Effects
1
Cardiotoxicity After Childhood
Cancer Treatment
Kelley K. Hutchins, Rudolf Steiner,
Emma R. Lipshultz, Stephen E. Sallan,
and Steven E. Lipshultz
1.1 Introduction are surviving longer than 5 years in some devel-
oped nations, whereas these malignancies were
Childhood cancer survivorship has become a nearly universally fatal prior to the 1960s.
great success story over the past few decades. Unfortunately, with this amazing success has
More than 80% of patients with childhood cancer come appreciation of the adverse late effects of
cancer therapies. Survivors of childhood cancer
have markedly higher rates of morbidity and
K. K. Hutchins mortality than those of their healthy
Department of Pediatric Hematology/Oncology, John counterparts.
A. Burns School of Medicine, Kapi’olani Medical
One important adverse effect is cardiotoxic-
Center for Women and Children, Honolulu, HI, USA
e-mail: [email protected] ity. Heart failure, myocardial disease, valvular
disease, hypertension, and early cardiac death are
R. Steiner
University of Zurich, Zurich, Switzerland among the adverse cardiac outcomes that affect
e-mail: [email protected] an increasing number of childhood cancer survi-
E. R. Lipshultz vors. Cancer treatment, especially chemotherapy
University of Miami, Miller School of Medicine, and radiation, as well as several additional risk
Miami, FL, USA factors, puts survivors at substantially increased
e-mail: [email protected]
risk of cardiotoxicity. Extensive screening guide-
S. E. Sallan lines have been developed to identify and treat
Department of Pediatric Oncology, Dana-Farber
these patients as early and effectively as possible.
Cancer Institute, Boston, MA, USA
e-mail: [email protected] Current position papers and guidelines, how-
ever, are consensus-based, and their ability to
S. E. Lipshultz (*)
A. Conger Goodyear Chair, Department of Pediatrics, prevent cardiotoxicity or improve long-term out-
University at Buffalo Jacobs School of Medicine and comes needs to be validated. Several treatment
Biomedical Sciences; Pediatric Chief-of-Service, modalities have also been proposed to reduce
Kaleida Health; Medical Director of Pediatric
therapy- induced cardiotoxicity, but many are not
Services Business Development, John R. Oishei
Children’s Hospital; President, UBMD Pediatrics evidence-based. One effective cardioprotectant is
Medical Group Consultant in Pediatrics and dexrazoxane. Further research is needed to deter-
Cardio-oncology, Roswell Park Comprehensive mine the best means of preventing, screening for,
Cancer Center, Buffalo, NY, USA
and treating cardiotoxicity among childhood can-
e-mail: [email protected];
[email protected] cer survivors.
© Springer Nature Switzerland AG 2021 3
J. D. Beck et al. (eds.), Late Treatment Effects and Cancer Survivor Care in the Young,
https://doi.org/10.1007/978-3-030-49140-6_1